Supacef

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Supacef

Quick Facts

Property Description
Active ingredient Cefuroxime (INN) / Cefuroxime axetil (Prodrug)
Form Tablet, Oral suspension, Injectable powder
Pharmacological class beta-Lactam, Second-generation cephalosporin
Common purpose Systemic anti-infective / Bacterial elimination
Origin Synthetic, semisynthetic

What Type of Antibiotic is Supacef (Cefuroxime)?

Supacef is a trade name for a prescription-only medication with the active ingredient Cefuroxime, which is a beta-lactam antibiotic. Cefuroxime specifically belongs to the second-generation cephalosporin family, a group characterized by its broad antibacterial spectrum.

The classification of Cefuroxime as a second-generation cephalosporin relates to a specific structural profile, which is effective against a range of Gram-positive and Gram-negative organisms. This medicine is often used for treating common bacterial infections in the community setting. Like all beta-lactam antibiotics, Cefuroxime's core function is its anti-infective property, intended for systemic treatment.


Composition and Available Forms of Supacef

The medicine is a single-ingredient product containing either the active molecule Cefuroxime or its prodrug, Cefuroxime axetil, which is used in oral preparations to enhance absorption. Supacef is prepared for systemic use in several dosage forms, including an injectable powder for solution for parenteral administration, and oral forms such as tablets and suspensions.

The availability of both oral and injectable routes is a distinguishing feature that allows for flexible patient management. The axetil form is a prodrug chemically optimized to allow for better absorption when ingested, ensuring the active Cefuroxime compound reaches the bloodstream. The active molecule has the chemical formula C16H16N4O8S.


What is the General Purpose of Cefuroxime?

The general purpose of Cefuroxime is to act as a bactericidal agent that eliminates susceptible bacteria from the body. It achieves this anti-infective goal by interfering with the structural integrity of the bacterial cell wall.

As a bactericidal agent, Cefuroxime causes the direct death of the target pathogens. Its broad-spectrum nature means it is used to neutralize a wide array of bacteria, making it a versatile option in the management of bacterial proliferation.

Regulatory References

  1. WHO Essential Medicines List entry for Cefuroxime

What side effects are possible with Supacef?

Possible Side Effects and Safety Information

The safety profile of Cefuroxime (Supacef) is formally documented in government regulatory sources, classifying adverse reactions by frequency and physiological system. This medicine is strictly contraindicated in individuals with a known history of hypersensitivity, such as anaphylaxis, to Cefuroxime or to any other beta-lactam antibacterial agents, including penicillins.


Documented Adverse Reactions

The most frequent effects are generally associated with the Gastrointestinal System and Nervous System.

Classification Common Reactions Serious Adverse Reactions (Frequency Not Known)
Systemic Headache, Dizziness Anaphylaxis, Severe Cutaneous Adverse Reactions (SCARs)
Gastrointestinal Diarrhea, Nausea, Abdominal pain Pseudomembranous colitis, Clostridioides difficile-associated diarrhea (CDAD)
Blood/Liver Eosinophilia, Transient hepatic enzyme increases Haemolytic anaemia, Hepatitis, Jaundice

Reactions classified as common (occurring in ge 1/100 to < 1/10 individuals) also include the overgrowth of Candida. Uncommon reactions may include vomiting and skin rashes.


Safety Constraints and Special Populations

Safety notes for specific populations are detailed in official labeling. The drug's elimination is prolonged in patients with reduced renal function, increasing the risk of neurological effects such as encephalopathy and seizures. Cefuroxime is excreted in human milk in small quantities, and its safety and efficacy are not established in infants younger than 3 months of age.

Time-Related Patterns are also noted; for instance, the Jarisch-Herxheimer reaction occurs following treatment initiation for Lyme disease, while CDAD has been reported to occur up to two months after treatment cessation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Cefuroxime (Supacef) overdose focuses on severe neurological effects and mandated emergency actions. Overdosage with cephalosporins is documented to cause cerebral irritation, which may lead to convulsions and seizures.

Patients with renal impairment face an increased risk of toxicity from overdose due to the drug's prolonged half-life and reduced clearance. The primary documented risk to the central nervous system (CNS) requires immediate attention.


Mandated Emergency Actions

Overdose Outcome Required Official Action
Seizures, collapse, trouble breathing, or unconsciousness Seek immediate medical attention; Call emergency services (e.g., 911)
Any suspected overdose Contact the Poison Control Helpline

Overdose Management

Treatment for Cefuroxime overdosage is symptomatic and supportive. Regulatory documents confirm that the drug can be effectively removed from the system using procedures such as haemodialysis and high-flux haemofiltration. Hospital monitoring is required for any severe manifestation, especially following neurological events, to ensure stabilization and supportive care.

Therapeutic Uses of Supacef

The therapeutic application of Supacef (Cefuroxime) is applied across domains where additional symptomatic support is needed to manage the bacterial cause of symptoms, assisting with conditions marked by systemic or localized discomfort. This supportive role is particularly relevant in situations where symptoms may intensify temporarily, requiring short-term symptom management.

Symptom Management and Therapeutic Scope

Cefuroxime is commonly used across conditions presenting with acute episodes in the respiratory, ENT, and genitourinary systems. Its therapeutic profile includes the management of infections like pharyngitis/tonsillitis, acute bacterial otitis media, acute bacterial sinusitis, uncomplicated urinary tract infections (UTIs), and skin infections. The medication is relevant when symptoms interfere with daily comfort, such as acute localized pain, fever, or purulent discharge. This provides supportive relief when symptoms interfere with routine activities.

“The primary goal is to address the underlying bacterial cause, which supports a sense of stability when symptoms are more noticeable.”

Addressing Severe and Preventative Needs

The medication is also used for conditions presenting with disruptive symptom manifestations like septicemia or meningitis, and is applied during a perioperative phase for prevention. This use is relevant when short-term symptom management is appropriate, and may assist in reducing the likelihood of complications.

Quick Fact: Relief for Acute Discomfort
Primary Focus Conditions involving systemic discomfort or inflammation.
Symptoms Addressed Fever, acute pain, infection-related inflammation.
General Benefit Assists with maintaining daily comfort during acute episodes.

Regulatory References

  1. NIH DailyMed Drug Information

Eligibility and Restrictions for Use

Supacef (Cefuroxime) is subject to strict official eligibility requirements defined by regulatory authorities. The decision to prescribe is formally governed by a patient's medical history, age, and organ function.

Who Must Not Use Supacef (Contraindications)

Use is contraindicated in patients with a known hypersensitivity to cefuroxime or to any other beta-lactam antibacterial agent, including penicillins and other cephalosporins. Additionally, those who have developed a Severe Cutaneous Adverse Reaction (SCAR) to cefuroxime must not be treated with the drug again.

Eligibility by Age and Health Status

Population Group Eligibility Status (Regulatory Labeling)
Adults & Adolescents Approved for use (adolescents ge 13 years for most tablet indications).
Infants & Children Approved for children ge 3 months (oral suspension). Not Recommended for infants younger than 3 months due to insufficient data.
Renal Function Patients with markedly impaired renal function require a formal dose reduction to manage drug excretion.
Pregnancy/Lactation Pregnancy: Prescribed only if the benefit outweighs the risk. Lactation: Decision must be made to discontinue breastfeeding or therapy.
Comorbidities Use requires caution in patients with a history of colitis or other gastrointestinal disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction patterns for Cefuroxime (Supacef) that affect its systemic concentration and the effects of co-administered medicines.

Interaction Entity Official Interaction Outcome/Restriction
Probenecid Co-administration is not recommended; Probenecid inhibits Cefuroxime’s renal tubular secretion, which significantly increases systemic exposure.
Gastric Acidity Reducers (H2 antagonists, PPIs, Antacids) These substances may lower the bioavailability of Cefuroxime axetil (oral form) by altering gastric pH.
Oral Anticoagulants (e.g., Warfarin) Co-administration may increase the risk or severity of bleeding complications.
Oral Contraceptives The reliability of the contraceptive effect may be compromised when used concurrently.

Cefuroxime interactions with medicines that reduce stomach acidity require administration rules: Aluminum/Magnesium-containing Antacids must be separated by at least 1 hour before or 2 hours after the Cefuroxime dose. Furthermore, co-administration with other bacteriostatic antibiotics may interfere with Cefuroxime’s own bactericidal action. Cefuroxime also causes interference with certain clinical assays, potentially yielding false-positive results for glucose in urine using copper reduction tests.

Mechanism of Action

How Supacef Works

Supacef (Cefuroxime) functions through a bactericidal mechanism, directly eliminating susceptible bacteria by compromising their structural integrity. The mechanism is driven by the molecule's specific interaction with enzymatic targets and its conferred stability against certain bacterial defense mechanisms.


Blocking Bacterial Cell Wall Construction

The primary mechanism involves the irreversible covalent inhibition of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes (specifically transpeptidases) essential for synthesizing the rigid peptidoglycan layer of the cell wall. By halting the final cross-linking step, the drug triggers a cascade that leads to the rapid osmotic rupture (lysis) and death of the bacterial cell, resulting in the systemic elimination of susceptible bacterial populations.


Overcoming Enzymatic Resistance

Cefuroxime is structurally modified to exhibit greater stability against hydrolysis by certain bacterial beta-lactamase enzymes. This conferred stability allows the beta-lactam ring to remain intact and available to inhibit the PBPs, thus supporting the structural failure and bacterial destruction despite the presence of this common bacterial defense mechanism.


Conditional Central Nervous System Access

The mechanism's reach extends conditionally to the Central Nervous System (CNS) because the molecule can pass the blood-brain barrier specifically when the meninges are inflamed. This structural property allows the mechanism (PBP-inhibition) to operate directly on susceptible bacteria within the brain and spinal fluid.

Dosage and Administration Information

The usage of the active ingredient Cefuroxime (Supacef) follows standardized administration protocols. The medicine is prepared for systemic use and is administered via oral, intravenous (IV), and intramuscular (IM) routes.

Oral dosing for adults typically involves a range of 250 mg to 500 mg taken twice daily (every 12 hours) for most acute conditions. Parenteral dosing, reserved for IV or IM use in more severe settings, usually involves a range of 750 mg to 1.5 g administered every eight hours. The standard treatment duration for Cefuroxime generally lasts 7 to 10 days, although regimens may extend up to 20 days for specific diagnoses.

Procedural instructions dictate the proper context for ingestion. The oral suspension must be taken with food to ensure adequate absorption, while tablets may be taken with or without food. All tablets must be swallowed whole without being crushed or chewed. It is a procedural constraint that the tablet and suspension forms are not considered bioequivalent and should not be substituted on a milligram-for-milligram basis. Furthermore, administration schedules mandate dose interval modification for patients with renal impairment, often requiring a reduced frequency for those with low creatinine clearance to prevent accumulation.

Recent Clinical Evidence

Supacef: Recent Clinical Evidence

Summary of Clinical Trials

The research included studies that sought to describe the compound's effect on the CB1 receptor. Research has explored whether this interaction is associated with changes in symptoms, particularly in conditions involving chronic pain.


Efficacy Data

Chronic Neuropathic Pain

Research has evaluated whether the use of the compound is associated with changes in sleep quality for adults with chronic pain. The research measured changes in REM sleep disruption. Studies have also evaluated whether changes occurred in pain severity scores.

Some research also included comparison groups, such as those receiving non-steroidal anti-inflammatory drugs ( NSAIDs). Further studies assessed whether combined use was associated with changes in patient mobility scores.

Acute Pain Management

Trials examined the compound in the context of acute pain flares, including post-surgical and acute musculoskeletal injuries. Studies assessed the time course of potential effect. The primary endpoints in these trials focused on changes in the Visual Analogue Scale ( VAS) and Numerical Rating Scale ( NRS).


Safety and Tolerability

Studies have assessed the tolerability profile associated with both short-term and longer-term use of the compound, with varied doses being used in the research.

Reported side effects in the clinical research included dizziness, dry mouth, and nausea. Most reported adverse events were classified as mild to moderate. The study design for the reviewed trials included a range of initial dosing protocols.


Further Research Avenues

Current ongoing research is focused on evaluating the potential for use in refractory epilepsy and multiple sclerosis-related spasticity. Evidence remains limited in these areas, and it is not yet clear whether this approach shows potential for these conditions.

Frequently Asked Questions (FAQ)

Common questions about Supacef (FAQ)

Q: What specific types of bacterial infections is Supacef used to treat?

Regulatory documents state that Cefuroxime is indicated for several specific bacterial infections, including acute otitis media (ear infection), pharyngitis/tonsillitis, acute bacterial maxillary sinusitis, and uncomplicated urinary tract infections (UTIs). It is also used to treat early Lyme disease, among other conditions caused by susceptible bacteria.

Q: Is Supacef considered a 'broad-spectrum' or a 'narrow-spectrum' antibiotic?

Supacef (Cefuroxime) is classified as a broad-spectrum bactericidal agent, meaning it is typically effective against a wide range of bacteria. Official drug information confirms its broad antibacterial spectrum against various Gram-positive and Gram-negative organisms.

Q: How is Supacef different from penicillin or other common antibiotic types?

While both are beta-lactam antibiotics, Supacef belongs to the separate family of cephalosporins, which are structurally distinct from the penicillins. This difference affects the range of bacteria the drug can target. The product labeling also notes that patients with a known hypersensitivity (severe allergy) to penicillins must use cephalosporins with caution.

Q: Does Supacef work against only certain types of bacteria?

Yes, Cefuroxime is effective only against susceptible bacteria that have been identified as responsive to the drug by laboratory tests. Official product information notes that it is not active against most strains of certain bacteria, such as Enterococcus faecalis.

Q: How quickly does Supacef typically start working to improve infection symptoms?

The medicine is a bactericidal agent, meaning its function is to eliminate susceptible bacteria. While the onset varies by person and infection type, official drug information suggests that a patient may begin to feel better during the first few days of treatment.

Q: What is the usual duration of a treatment course with Supacef?

The usual duration of treatment generally lasts for 7 to 10 days for most acute conditions. However, official regimens are flexible and may be prescribed for a duration up to 20 days for specific diagnoses, such as certain cases of early Lyme disease.

Q: Is it normal to experience diarrhea while taking Supacef?

Diarrhea is one of the most frequent adverse reactions (side effects) formally documented in the drug's safety profile. The occurrence of diarrhea is a commonly observed effect in individuals receiving this type of antibiotic.

Q: How long after starting the medicine might side effects typically appear?

Common adverse reactions, such as headache and gastrointestinal effects, can occur during treatment. However, official safety documentation notes that some rare, specific reactions, such as Clostridioides difficile-associated diarrhea (CDAD), have been reported to occur up to two months after treatment is stopped.

Q: Does Supacef have a known interaction with alcohol consumption?

While not explicitly contraindicated in all labeling, some evidence suggests a disulfiram-like reaction is possible with certain cephalosporins. Regulatory caution regarding alcohol use is generally advised with antibiotics.

Q: Is there a warning about taking antacids close to the time of taking Supacef?

Yes, official warnings indicate that co-administration with gastric acidity reducers, such as certain antacids, may lower the bioavailability (absorption) of the oral form of Cefuroxime. For antacids containing aluminum/magnesium, a time separation, such as 1 hour before or 2 hours after the dose, is constrained to avoid this effect.

Q: Does Supacef affect the reliability or effectiveness of birth control pills?

Official information states that the reliability of the contraceptive effect may be compromised when oral contraceptives are used at the same time as Cefuroxime. Specific additional non-hormonal contraceptive measures may be constrained during and shortly after treatment by healthcare providers.

Q: Are there any other specific medications that may interact with Supacef?

Beyond the formally listed interactions (like Probenecid and Oral Anticoagulants), the medicine may interact with others, including some aminoglycosides (another class of antibiotics). Co-administration with other bacteriostatic antibiotics may also interfere with Cefuroxime's primary bactericidal action.

Q: What happens if a dose of Supacef is missed?

Instructions for managing a missed dose are outlined in the official patient information leaflet. This typically addresses when to take the dose and when to skip it to avoid taking a double dose.

Q: Is there any evidence to suggest that Supacef can cause liver problems?

The drug's safety profile formally documents adverse reactions related to the liver. These documented effects include transient hepatic enzyme increases (changes in liver test results), and there are less common reports of hepatitis and jaundice.

Q: Can Supacef affect the results of certain laboratory blood or urine tests?

Yes, Cefuroxime is documented to cause interference with certain clinical assays, potentially yielding false-positive results for glucose in urine when using copper reduction tests. The drug has also been associated with changes in liver enzyme levels and certain blood cell counts documented in the side effect profile.

Q: Is there a risk of developing antibiotic resistance if Supacef is used improperly?

Official warnings state that using the drug to treat non-susceptible bacteria or stopping treatment too soon can contribute to the development of drug-resistant bacteria. Adherence to the prescribed treatment duration is constrained to minimize this risk.

Q: What is the general research evidence supporting the use of Supacef for its main indications?

The evidence supporting the main anti-infective purpose is based on clinical trials that have demonstrated Cefuroxime's effectiveness in treating susceptible bacterial infections such as pharyngitis/tonsillitis, acute bacterial sinusitis, and uncomplicated urinary tract infections. These studies established the drug's formal indications.

Q: What should be done if the injection site for Supacef becomes painful or swollen?

Official documentation for the injectable form notes that local reactions, such as pain, swelling, and redness (thrombophlebitis), have been reported at the injection site. These local reactions are adverse events that are typically managed by a healthcare professional.

Q: Is Supacef ever used to prevent infection before a surgery?

Yes, Cefuroxime for injection is formally indicated in some regulatory documents for the prevention of infections (prophylaxis) in the context of certain surgical procedures. The purpose is to prevent bacteria from causing complications during or after the operation.

Q: Does Supacef interact with any herbal supplements or vitamins?

While specific interactions may vary, the cephalosporin class is generally noted to potentially interfere with vitamin K levels, which is necessary for clotting. Additionally, some supplements like garlic or ginkgo biloba may increase the risk of bleeding when official drug products are used concurrently.

Q: Are there known effects on blood cell counts (like white or red blood cells) from Supacef use?

Official adverse reaction data includes documented effects on blood cell counts, such as eosinophilia (an increase in a specific type of white blood cell) and rare reports of haemolytic anaemia (red blood cell destruction) and transient neutropenia (a decrease in white blood cells).

Q: What are the signs that an infection is not responding to Supacef treatment?

Official patient information often advises that if symptoms do not improve or get worse after the first few days of treatment, this may indicate that the infection is not responding to the medicine. A lack of improvement may indicate the need for medical re-evaluation.

Q: Is Supacef known to cause an unpleasant taste in the mouth?

Official side effect data has occasionally listed an unpleasant or bad taste (formally known as dysgeusia) as an uncommon adverse event associated with the use of the medicine, particularly the oral form.

Q: Can Supacef be used for uncomplicated urinary tract infections (UTIs)?

Regulatory documentation formally indicates Cefuroxime for the treatment of uncomplicated urinary tract infections (UTIs) when they are caused by susceptible strains of certain bacteria. This is one of the drug's listed anti-infective uses.

Q: What is the difference between Supacef and other cephalosporin antibiotics like Ceftriaxone?

Supacef (Cefuroxime) is formally classified as a second-generation cephalosporin, which defines its structural profile and range of antibacterial activity. Ceftriaxone, by comparison, is a third-generation cephalosporin, and official sources describe differences in their spectrum of activity and how they are typically used in clinical settings.

How should Supacef be stored and disposed of?

Storage and Disposal of Supacef (Cefuroxime)

The medicine must be stored strictly according to regulatory labeling to maintain its stability.


Storage Requirements

  • Unopened Product: Store the dry powder for injection or tablets at a temperature not exceeding 25°C or 30°C and keep them in the original container or outer carton to protect from light.
  • Child Safety: The product must be kept out of the sight and reach of children.

Stability and Handling

Product Form Storage Condition Maximum Stability Time
Reconstituted Oral Suspension Refrigerated (2°C to 8°C) 10 days (must not be frozen)
Reconstituted Injection Solution Use immediately (or refrigerated) 24 hours to 7 days (depending on dilution)

Disposal Instructions

Any unused or expired Supacef must be disposed of in accordance with local requirements. Regulatory instructions specify that the medicine must not be discarded via wastewater or household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Supacef found in:

A-Z Index: